請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/81824完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳進庭(Chin Tin Chen) | |
| dc.contributor.author | Ling-Jei Meng | en |
| dc.contributor.author | 孟令潔 | zh_TW |
| dc.date.accessioned | 2022-11-25T03:04:26Z | - |
| dc.date.available | 2024-07-27 | |
| dc.date.copyright | 2021-08-18 | |
| dc.date.issued | 2021 | |
| dc.date.submitted | 2021-07-29 | |
| dc.identifier.citation | Davis, C. P. Normal Flora. Medical Microbiology, 4th ed. 1996, Chapter 6. University of Texas Medical Branch at Galveston. Tancrède C. Role of human microflora in health and disease. European journal of clinical microbiology infectious diseases. 1992, 11(11), 1012–1015 Akpan, A., Morgan, R. Oral candidiasis. Postgraduate medical journal. 2002, 78(922), 455–459. 台灣院內感染監視資訊系統 (TNIS系統) 2019年第3季監視報告 de Oliveira Santos, G. C., Vasconcelos, C. C., Lopes, A., de Sousa Cartágenes, M., Filho, A., do Nascimento, F., Ramos, R. M., Pires, E., de Andrade, M. S., Rocha, F., de Andrade Monteiro, C. Candida Infections and Therapeutic Strategies: Mechanisms of Action for Traditional and Alternative Agents. Frontiers in microbiology. 2018, 9, 1351. Spampinato, C., Leonardi, D. Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. BioMed research international. 2013, 204237. Hui Chen., Xuedong Zhou., Biao Ren., Lei Cheng. The regulation of hyphae growth in Candida albicans. Virulence. 2020, 11(1), 337-348. Lo, H. J., Köhler, J. R., DiDomenico, B., Loebenberg, D., Cacciapuoti, A., Fink, G. R. Nonfilamentous C. albicans Mutants Are Avirulent. Cell, 1997. 90(5), p939-949. Noble, S. M., Gianetti, B. A., Witchley, J. N. Candida albicans cell-type switching and functional plasticity in the mammalian host. Nature reviews. Microbiology. 2017, 15(2), 96–108. Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., Edmond, M. B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clinical infectious diseases. 2004, 39(3), 309–317. 柯冠伶 (2010年7月)。念珠菌菌血症之危險因子以及臨床治療結果分析：著重於抗黴菌藥物之治療對於預後之成效影響。國立台灣大學。 O'Toole, G., Kaplan, H. B., Kolter, R. Biofilm formation as microbial development. Annual review of microbiology. 2000, 54, 49–79. Sardi JCO., Scorzoni L., Bernardi T., Fusco-Almeida AM., Mendes Giannini MJS. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol. 2013 Jan, 62(Pt 1), 10-24 Kojic, E. M., Darouiche, R. O. Candida infections of medical devices. Clinical microbiology reviews. 2004, 17(2), 255–267. Zhao, X., Oh, S. H., Yeater, K. M., Hoyer, L. L. Analysis of the Candida albicans Als2p and Als4p adhesins suggests the potential for compensatory function within the Als family. Microbiology. 2005, 151(Pt 5), 1619–1630. 黃宜真 (2016年7月)。結合光動力殺菌與Fluconazole在白色念珠菌的治療效果探討。國立台灣大學。 Ramage, G., Vande Walle, K., Wickes, B. L., López-Ribot, J. L. Biofilm formation by Candida dubliniensis. Journal of clinical microbiology. 2001, 39(9), 3234–3240. Baillie, G. S., Douglas, L. J. Role of dimorphism in the development of Candida albicans biofilms. Journal of medical microbiology. 1999, 48(7), 671–679. Tsui, C., Kong, E. F., Jabra-Rizk, M. A. Pathogenesis of Candida albicans biofilm. Pathogens and disease. 2016, 74(4), ftw018. Mukherjee, P. K., Chandra, J. Candida biofilm resistance. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2004, 7(4-5), 301–309. Silva, S.; Rodrigues, C.F.; Araújo, D.; Rodrigues, M.E.; Henriques, M. Candida Species Biofilms’ Antifungal Resistance. J. Fungi. 2017, 3, 8. Mah, T. F., O'Toole, G. A. Mechanisms of biofilm resistance to antimicrobial agents. Trends in microbiology. 2001, 9(1), 34–39. George S. Baillie., L. Julia Douglas. Effect of Growth Rate on Resistance of Candida albicans Biofilms to Antifungal Agents. Antimicrobial Agents and Chemotherapy. 1998, 42(8), 1900-1905. Sanglard D. Mechanisms of Drug Resistance in Candida albicans. In: Prasad R. (eds) Candida albicans: Cellular and Molecular Biology. 2017, pp 287 – 311. D G Allison., P Gilbert. Modification by surface association of antimicrobial susceptibility of bacterial populations, Journal of Industrial Microbiology. 1995, Volume 15, Issue 4, Pages 311–317. Akyol Erikci, A.; Ozyurt, M.; Terekeci, H.; Ozturk, A.; Karabudak, O.; Oncu, K. Oesophageal aspergillosis in a case of acute lymphoblastic leukaemia successfully treated with caspofungin alone due to liposomal amportericin B induced severe hepatotoxicity. Mycoses. 2009, 52, (1), 84-86. Cohen, B. E. Amportericin B toxicity and lethality: a tale of two channels. Int J Pharm. 1998, 162, (1-2), 95-106. Vermes, A., Guchelaar, H. J., Dankert, J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. The Journal of antimicrobial chemotherapy. 2000, 46(2), 171–179. P.D. Crowley, H.C. Gallagher. Clotrimazole as a pharmaceutical: past, present and future. Journal of Applied Microbiology. 2014, Volume 117, Issue3, Pages 611—617. Clarissa J. Nobile and Alexander D. Johnson. Candida albicans Biofilms and Human Disease. Annual Review of Microbiology. 2015, 69, 71-92 Kaewbanjong, J., Amnuaikit, T., Souto, E. B., Boonme, P. Antidermatophytic Activity and Skin Retention of Clotrimazole Microemulsion and Microemulsion-Based Gel in Comparison to Conventional Cream. Skin Pharmacol Physiol. 2018, 31(6), 292–297. Simonazzi, A., Cid, A. G., Villegas, M., Romero, A. I., Palma, S. D., Bermúdez, J. M. Nanotechnology applications in drug controlled release. Drug Targeting and Stimuli Sensitive Drug Delivery Systems. 2018, 81–116. Paradkar, M., Thakkar, V., Soni, T., Gandhi, T., Gohel, M. Formulation and evaluation of clotrimazole transdermal spray. Drug Development and Industrial Pharmacy. 2015, 41(10), 1718-1725. Bolla, P. K., Meraz, C. A., Rodriguez, V. A., Deaguero, I., Singh, M., Yellepeddi, V. K., Renukuntla, J. Clotrimazole Loaded Ufosomes for Topical Delivery: Formulation Development and In-Vitro Studies. Molecules. 2019, 24, 3139 Aakhus, A. E., Warshaw, E. M. Allergic Contact Dermatitis from Cetyl Alcohol. Dermatitis. 2011, 22(1), 56–57. Dawn, G., Forsyth, A. Genital swelling caused by octyldodecanol contact dermatitis. Clinical and Experimental Dermatology. 2003, 28(2), 228–229. Mayba JN, Gooderham MJ. A Guide to Topical Vehicle Formulations. J Cutan Med Surg. 2018 Mar/Apr, 22(2), 207-212. Tsume, Y., Mudie, D. M., Langguth, P., Amidon, G. E., Amidon, G. L. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2014, 57, 152–163. Hina Shrestha., Rajni Bala., Sandeep Arora. Lipid-Based Drug Delivery Systems. Journal of Pharmaceutics. 2014, vol. 10 pages. Porter, C., Trevaskis, N. Charman, W. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 6. 2007, 231–248. Ahmad, A., Ahsan, H. Lipid-based formulations in cosmeceuticals and biopharmaceuticals. biomed dermatol 4. 2020, 12. Dokania, S. and A.K. Joshi. Self-microemulsifying drug delivery system (SMEDDS) – challenges and road ahead. Drug Delivery. 2015, 22(6): p.675-90. Pouton CW., Porter CJ. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv Drug Deliv Rev. 2008, 60(6), 625-37. Vithani K., Jannin V., Pouton CW., Boyd BJ. Colloidal aspects of dispersion and digestion of self-dispersing lipid-based formulations for poorly water-soluble drugs. Adv Drug Deliv Rev. 2019 Mar, 142, 16-34. Andrade Santana, M.H. Self-Emulsifying Drug Delivery Systems (SEDDS) in Pharmaceutical Development. Journal of Advanced Chemical Engineering. 2015, 5(3). Akula, S., Gurram, A. K., Devireddy, S. R. Self-Microemulsifying Drug Delivery Systems: An Attractive Strategy for Enhanced Therapeutic Profile. International scholarly research notices. 2014, 964051. van Staden, D., du Plessis, J., Viljoen, J. Development of Topical/Transdermal Self-Emulsifying Drug Delivery Systems, Not as Simple as Expected. Sci. Pharm. 2020, 88, 17. Kumar M., Bishnoi RS, Shukla AK., Jain CP. Techniques for Formulation of Nanoemulsion Drug Delivery System: A Review. Prev Nutr Food Sci. 2019 Sep, 24(3), 225-234. Thakkar, H., Nangesh, J., Parmar, M., Patel, D. Formulation and characterization of lipid-based drug delivery system of raloxifene-microemulsion and self-microemulsifying drug delivery system. Journal of pharmacy bioallied sciences. 2011, 3(3), 442–448. Tan BH, Chakrabarti A., Li RY., Patel AK., Watcharananan SP., Liu Z., Chindamporn A., Tan AL., Sun PL., Wu UI., Chen YC; Asia Fungal Working Group (AFWG). Incidence and species distribution of candidaemia in Asia: a laboratory-based surveillance study. Clin Microbiol Infect. 2015 Oct, 21(10), 946-53. Chen PY., Chuang YC., Wang JT., Sheng WH., Yu CJ., Chu C.C, Hsueh PR., Chang SC., Chen YC. Comparison of epidemiology and treatment outcome of patients with candidemia at a teaching hospital in Northern Taiwan, in 2002 and 2010. J Microbiol Immunol Infect. 2014 Apr, 47(2), 95-103. Bachhav YG., Patravale VB. Microemulsion-based vaginal gel of clotrimazole: formulation, in vitro evaluation, and stability studies. AAPS PharmSciTech. 2009, 10(2), 476-81. CLSI (2008a) Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-third edition; CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne. Method for antifungal disk diffusion susceptibility testing of yeasts: approved standard. Wayne, PA: Clinical and Laboratory Standards Institute; 2006. Clinical and Laboratory Standards Institute. CLSI M44-A. Stippler, E.S., Kopp, S., Dressman, J. Comparison of US Pharmacopeia Simulated Intestinal Fluid TS (without pancreatin) and Phosphate Standard Buffer pH 6.8, TS of the International Pharmacopoeia with Respect to Their Use in In Vitro Dissolution Testing. Dissolution Technologies. 2014, 11, 6-10. Aarti Naik., Louk A.R.M., Pechtol.d, Russell O. Potts., Richard H. Guy. Mechanism of oleic acid-induced skin penetration enhancement in vivo in humans. Journal of Controlled Release. 1995, Volume 37, Issue 3, Pages 299-306. Shivani Verma., Ankur Bhardwaj., Mohit Vij., Pawan Bajpai., Nishant Goutam., Lalit Kumar. Oleic acid vesicles: a new approach for topical delivery of antifungal agent,. Artificial Cells, Nanomedicine, and Biotechnology. 2014, 42(2), 95-101. Effendy, I., Maibach, H. I. Surfactants and experimental irritant contact dermatitis. Contact dermatitis. 1995, 33(4), 217–225. Cserháti, T., Forgács, E., Oros, G. Biological activity and environmental impact of anionic surfactants. Environment international. 2002, 28(5), 337-48. Lu, H., Zheng, C., Xue, M., Huang, Z. pH-regulated surface properties and pH-reversible micelle transition of a zwitterionic gemini surfactant in aqueous solution. Phys Chem Chem Phys. 2016, 18(47), 32192-32197. Diego F. Tirado., Amandine Rousset., Lourdes Calvo*. The Selective Supercritical Extraction of High-value Fatty Acids from Tetraselmis suecica using the Hansen Solubility Theory. Chemical engineering transactions. 2019, Volume 75. Alhijjaj, M., Belton, P., Qi, S. An investigation into the use of polymer blends to improve the printability of and regulate drug release from pharmaceutical solid dispersions prepared via fused deposition modeling (FDM) 3D printing. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2016, 108, 111–125. Hao Zhang., Xiaolong Lu., Zhiyu Liu., Zhong Ma., Song Wu., Zhendong Li., Xiao Kong., Juanjuan Liu., Chunrui Wu. The unidirectional regulatory role of coagulation bath temperature on cross-section radius of the PVDF hollow-fiber membrane. Journal of Membrane Science. 2018, Volume 550, Pages 9-17. Oleic acid [MAK Value Documentation, 2002]. In The MAK‐Collection for Occupational Health and Safety. 曾美容 (民國82年9月)。抗黴菌劑。藥學雜誌，第九卷第三期。 吳綺容、李欣純、柯文謙。念珠菌菌血症臨床處置的新進展。國立成功大學醫學院附設醫院。 McCarron, P. A., Donnelly, R. F., Marouf, W., Calvert, D. E. Anti-adherent and antifungal activities of surfactant-coated poly(ethylcyanoacrylate) nanoparticles. International journal of pharmaceutics. 2007, 340(1-2), 182–190. Muthamil, S., Prasath, K. G., Priya, A., Precilla, P., Pandian, S. K. Global proteomic analysis deciphers the mechanism of action of plant derived oleic acid against Candida albicans virulence and biofilm formation. Scientific reports. 2020, 10(1), 5113. Høiby, N., Ciofu, O., Johansen, H. K., Song, Z. J., Moser, C., Jensen, P. Ø., Molin, S., Givskov, M., Tolker-Nielsen, T., Bjarnsholt, T. The clinical impact of bacterial biofilms. International journal of oral science. 2011, 3(2), 55–65. P. Rajak*., L. K. Nath., B. Bhuyan. Liquid Crystals: An Approach in Drug Delivery. Indian J Pharm Sci. 2019, 81(1), 11-21 | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/81824 | - |
| dc.description.abstract | " 白色念珠菌 (Candida albicans) 為念珠菌屬中的一種微生物，是人體內常見的伺機性病原菌之一。有研究指出白色念珠菌所造成的死亡率大約是四成，目前主要的治療方法為使用抗真菌劑治療。而作為念珠病感染的局部第一線用藥克霉唑 (Clotrimazole, CTZ) 是唑類抗真菌藥物中的一種，屬於親脂性藥物，溶解度的問題限制了其在抗真菌治療的應用。CTZ在目前市售產品及文獻中，主要是藉由能承載親脂性藥物的遞送載體，如：油膏 (ointment) 或是乳膏 (cream) 等。這些較為油膩的製劑容易造成患者產生不適感，或是因所添加之賦形劑 (excipient) 產生過敏反應等。本研究藉由實驗室先前發展的脂質載體來進行CTZ的劑型改良。實驗結果發現改良的新劑型不僅於嚴苛環境下仍保持良好的穩定性外，其藥物最大承載量甚至可比市售產品高出10倍。此外，將CTZ新劑型與CTZ loaded DMSO相比，也可發現新劑型的最小抑菌濃度MIC50能降低4倍。接著，於紙錠擴散法實驗結果得知，新劑型不論是作用於白色念珠菌、熱帶念珠菌或是兩者之抗藥性菌株上，皆具有比市售乳膏產品更好的抑菌效果，顯示了CTZ新劑型具有多元的應用價值。而在生物膜形成的試驗中，也發現了CTZ新劑型不僅能降低白色念珠菌生物膜生成的能力，於高濃度之下也能破壞較為完整的生物膜結構。綜合上述，本研究發現CTZ新劑型在各項抑菌試驗中皆表現優異，具有良好的發展潛力。" | zh_TW |
| dc.description.provenance | Made available in DSpace on 2022-11-25T03:04:26Z (GMT). No. of bitstreams: 1 U0001-2807202112573000.pdf: 7611857 bytes, checksum: 6f98b7c40a1630032a1fd7a3f8ef9a8e (MD5) Previous issue date: 2021 | en |
| dc.description.tableofcontents | 致謝 .....i 中文摘要 .....ii Abstract .....iii 目錄 .....iv 圖目錄 .....ix 表目錄 .....xi 第一章、緒論 .....1 1.1 人類與微生物 .....1 1.1.1微生物感染 .....1 1.2 念珠菌屬 .....2 1.2.1 白色念珠菌 .....2 1.3 生物膜 .....3 1.3.1 生物膜的發展過程 .....3 1.3.2 生物膜的抗藥性機制 .....4 1.4 抗真菌藥物 .....6 1.4.1 抗真菌藥物的種類 .....6 1.4.2 克霉唑 .....7 1.5 局部製劑 .....8 1.5.1 脂質載體 .....8 第二章、研究動機與目的 .....10 第三章、實驗架構 .....12 第四章、材料與方法 .....13 4.1 菌種來源、保存與活化 .....13 4.1.1 菌種來源 .....13 4.1.2 菌種保存 .....13 4.1.3 菌種活化 .....13 4.2 實驗材料與儀器 .....14 4.2.1 材料與藥品 .....14 4.2.2 儀器 .....15 4.3 實驗方法 .....16 4.3.1 Clotrimazole分析方法 .....16 4.3.1.1 檢量線配製 .....16 4.3.1.2 標準曲線與藥量分析 .....16 4.3.2 Clotrimazole溶解度試驗 .....16 4.3.3 繪製三相圖 .....17 4.3.4 實驗藥品配製 .....17 4.3.4.1 Clotrimazole脂質載體 .....17 4.3.4.2 脂質載體配製 .....17 4.3.4.3 Clotrimazole二甲基亞碸原液 .....17 4.3.5 懸浮菌體培養 .....18 4.3.6 最小抑菌濃度測試 .....18 4.3.6.1 藥物最小抑菌濃度判讀標準 .....18 4.3.7 紙錠擴散法 .....19 4.3.7.1 藥物抑菌圈判讀標準 .....19 4.3.8 生物膜形成能力 .....19 4.3.9 特性分析 .....20 4.3.10 穩定性評估 .....20 4.3.10.1 長期外觀觀察 .....20 4.3.10.2 離心試驗 .....21 4.3.10.3 凍融循環 / 冷熱循環 .....21 4.3.10.4 藥物降解試驗 .....21 4.3.11 黏稠度試驗 .....21 4.3.11.1 添加聚合物 .....21 4.3.11.2 配製Clotrimazole液晶製劑 .....22 4.3.12 Clotrimazole液晶製劑之初步穩定性觀察及比例篩選 .....22 4.3.13 統計方法 .....22 第五章、實驗結果 .....23 5.1 發展Clotrimazole loaded LSF. .....23 5.1.1 篩選油相、界面活性劑以及助溶劑的依據 .....23 5.1.2 建立CTZ loaded LSF之三相圖 .....24 5.1.3 篩選CTZ loaded LSF之最佳比例 .....24 5.2 建立CTZ之藥物分析方法 .....25 5.3 探討CTZ loaded LSF35之抗菌效果 .....25 5.3.1 比較CTZ loaded LSF35與CTZ loaded DMSO 對白色念珠菌之MIC50差異 .....25 5.3.2 探討CTZ loaded LSF35組成對白色念珠菌之抑菌效果 .....26 5.3.2.1 探討CTZ loaded LSF35組成中兩兩賦形劑對白色念珠菌之抑菌效果 .....26 5.3.2.2 探討CTZ loaded LSF35組成中單一賦形劑對白色念珠菌之抑菌效果 .....26 5.3.2.3 探討Tween 80對白色念珠菌之抑菌效果 .....27 5.3.3 探討CTZ loaded LSF35與市售產品Mycosten®對白色念珠菌之抑菌圈效果 .....27 5.3.4 探討CTZ loaded LSF35與市售產品Mycosten®對抗藥性色念珠菌之抑菌圈效果 .....28 5.3.5 探討CTZ loaded LSF35與市售產品Mycosten®對熱帶念珠菌之抑菌圈效果 .....29 5.3.6 探討CTZ loaded LSF35與市售產品Mycosten®對抗藥性熱帶念珠菌之抑菌圈效果 .....29 5.3.7 探討CTZ loaded LSF35針對白色念珠菌生成之生物膜影響 .....30 5.3.7.1 探討CTZ loaded LSF35是否具有抑制白色念珠菌生成生物膜的能力 .....30 5.3.7.2 探討CTZ loaded LSF35是否能破壞白色念珠菌生成之生物膜 .....30 5.4 探討CTZ loaded LSF35於RPMI 1640培養液及人工腸液中之特性分析 .....30 5.5 探討CTZ loaded LSF35之安定性 .....31 5.5.1 一般性試驗評估CTZ loaded LSF35的穩定性 .....31 5.5.2 加速性試驗評估CTZ loaded LSF35的穩定性 .....31 5.5.3 探討CTZ loaded LSF35之藥物降解情形 .....32 5.6 探討於室溫下6個月後之CTZ loaded LSF35對野生株及抗藥性白色念珠菌的抑菌效果 .....32 5.7 探討CTZ loaded LSF35對白色念珠菌是否具有劑量依賴性 .....33 5.8 調整CTZ loaded LSF35之黏稠度 .....33 5.8.1 探討聚合物是否影響CTZ loaded LSF35之穩定性 .....33 5.8.2 配製CTZ loaded liquid crystal .....34 5.9 探討CTZ loaded liquid crystal之黏稠度與穩定性 .....34 5.10 探討CTZ loaded liquid crystal對白色念珠菌之抑菌效果 .....35 5.11 探討CTZ loaded liquid crystal-1對白色念珠菌、熱帶念珠菌及其抗藥性菌株之抑菌效果 .....35 5.12 探討於室溫下3個月後之CTZ loaded liquid crystal-1對野生株及抗藥性白色念珠菌的抑菌效果 .....36 第六章、討論. .....37 6.1 CTZ loaded LSF35配方探討 .....37 6.2 CTZ loaded LSF35對白色念珠菌之抗菌效果 .....38 6.3 CTZ loaded LSF35對白色念珠菌生物膜的抗菌效果探討 .....39 6.4 比較CTZ loaded LSF35及市售產品Mycosten®之抗菌效果 .....40 6.5 CTZ loaded LSF35與聚合物間不互溶的可能因素 .....40 6.6 CTZ loaded liquid crystal配方探討 .....41 6.7 比較CTZ loaded liquid crystal-1與CTZ loaded LSF35之抗菌效果 .....43 6.8 置於室溫3個月下之CTZ loaded liquid crystal-1抗菌效果 .....43 第七章、結論與未來研究方向 .....44 圖 .....45 表 .....71 參考文獻 .....76 附錄 .....84 | |
| dc.language.iso | zh-TW | |
| dc.subject | 克霉唑 | zh_TW |
| dc.subject | 生物膜 | zh_TW |
| dc.subject | 白色念珠菌 | zh_TW |
| dc.subject | Candida albicans | en |
| dc.subject | Biofilm | en |
| dc.subject | Clotrimazole | en |
| dc.title | 探討承載克霉唑之脂質載體對局部白色念珠菌感染的抗真菌效果 | zh_TW |
| dc.title | Evaluation of the antifungal efficacy of Clotrimazole loaded lipid based formulation against topical Candida albicans infection | en |
| dc.date.schoolyear | 109-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 吳亘承(Hsin-Tsai Liu),謝堅銘(Chih-Yang Tseng) | |
| dc.subject.keyword | 白色念珠菌,克霉唑,生物膜, | zh_TW |
| dc.subject.keyword | Candida albicans,Clotrimazole,Biofilm, | en |
| dc.relation.page | 93 | |
| dc.identifier.doi | 10.6342/NTU202101847 | |
| dc.rights.note | 同意授權(全球公開) | |
| dc.date.accepted | 2021-07-30 | |
| dc.contributor.author-college | 生命科學院 | zh_TW |
| dc.contributor.author-dept | 生化科技學系 | zh_TW |
| dc.date.embargo-lift | 2024-07-27 | - |
| 顯示於系所單位： | 生化科技學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-2807202112573000.pdf | 7.43 MB | Adobe PDF | 檢視/開啟 |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。